Cargando…
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Dapagliflozin [Farxiga(®) (USA); Forxiga(®) (EU)], a sodium–glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639555/ https://www.ncbi.nlm.nih.gov/pubmed/34651263 http://dx.doi.org/10.1007/s40256-021-00503-8 |